PipelineReview.com - Target Pipelines

Show Cart

Target Pipelines

Results 51 - 60 of 80

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

Mar 2018 Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing